Correction: Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials

There are errors in the author affiliations. The correct affiliations are as follows:

Samuel A. Danziger¹*, Mark McConnell¹, Jake Gockley², Mary H. Young¹, Adam Rosenthal³, Frank Schmitz¹, David J. Reiss¹, Phil Farmer⁴, Daisy V. Alapat⁴, Amrit Singh⁴, Cody Ashby⁴, Michael Bauer⁴, Yan Ren¹, Kelsie Smith¹, Suzana S. Couto⁵, Frits van Rhee⁴, Faith Davies⁴, Maurizio Zangari⁴, Nathan Petty⁴, Robert Z. Orlowski⁶, Madhav V. Dhodapkar⁷, Wilbert B. Copeland¹, Brian Fox¹, Antje Hoering³, Alison Fitch¹, Katie Newhall¹, Bart Barlogie⁸, Matthew W. B. Trotter⁹, Robert M. Hershberg¹⁰, Brian A. Walker⁴, Andrew P. Dervan¹, Alexander V. Ratushny¹‡*, Gareth J. Morgan⁴‡*

1 Bristol Myers Squibb, Seattle, Washington, United States of America

2 Sage Bionetworks, Seattle, Washington, United States of America

3 Cancer Research and Biostatistics, Seattle, Washington, United States of America

4 Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America

5 Genmab, Princeton, New Jersey, United States of America

6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

7 Winship Cancer Institute, Emory University, Atlanta, Georgia, United States of America

8 Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America

9 BMS Center for Innovation and Translational Research Europe (CITRE), Seville, Spain

10 Frazier Life Sciences, Seattle, Washington, United States of America